Argus
•
Feb 19, 2026
Gilead Sciences, Inc.: Raising target price to $165
Summary
Gilead Sciences is a biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is based i
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
Market Digest: AMP, EPD, FCX, FHI, LLY, RCL, WDC, WY, META, HCA
May 04, 2026
•
META, WY, AMP, FHI, HCA, WDC, LLY, EPD, RCL, FCX
Analyst Report: Eli Lilly & Co
May 04, 2026
•
LLY
Analyst Report: Moderna, Inc.
May 01, 2026
•
MRNA
Analyst Report: Amgen Inc.
May 01, 2026
•
AMGN
Market Digest: AAPL, AMT, CAKE, FE, KLAC, MGM, MSFT, QCOM, YUM, V, MA
May 01, 2026
•
MSFT, YUM, KLAC, AAPL, MGM, MA, QCOM, V, CAKE, AMT, FE
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus' bespoke research on IPOs.
